证券代码：873167 证券简称：新赣江 公告编号：2025-051 江西新赣江药业股份有限公司 投资者关系活动记录表 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、 投资者关系活动类别 □特定对象调研 √业绩说明会 参会单位及人员：投资者网上提问 上市公司接待人员：1、董事、总经理刘晓鹏 2、副总经理、董事会秘书严 棋鹏 3、财务总监程树平 4、保荐代表人方鸿斌。 □媒体采访 □现场参观 □新闻发布会 □分析师会议 □路演活动 □其他 二、 投资者关系活动情况 活动时间：2025 年 5 月 13 日 活动地点：公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） 采用网络远程的方式召开业绩说明会。 三、 投资者关系活动主要内容 本次业绩说明会通过年报视频解读等形式对公司情况及 2024 年经营业绩 情况进行了介绍。同时，公司就投资者在本次说明会中的提问进行了回复，主 要问题及回复如下： 问题 1：公司未来将如何给予投资者信心？ 回复：尊敬的投资者您好，公司将提高研发能力 ...

Group 1: Company Insights - 博实股份 reported a gross margin increase to 40% in Q1, driven by product structure adjustments and plans to enhance high-profit product promotion in overseas markets [1] - 云图控股 achieved record high sales of phosphate fertilizers in Q1, with significant recovery in profitability and ongoing projects for new fertilizer production [2] - 捷邦科技 acquired 49.90% of赛诺高德, integrating it into consolidated financials, and is focusing on carbon nanotube products for solid-state batteries [3] - 可孚医疗 is enhancing its core product strategy, with a focus on hearing aids and health monitoring, and plans to launch a new generation of ventilators in 2025 [4] - 三峰环境 expects a 65% increase in equipment sales revenue to 1.57 billion yuan in 2024, with international business revenue exceeding 100% growth [5] - 传音控股 reported a 25.45% decline in Q1 revenue to 13.004 billion yuan, primarily due to market competition and supply chain costs [6] - 宏发股份 indicated limited impact from the US-China tariff war, with plans to enhance profitability through product structure optimization and increased efficiency [7] - 完美世界's game titles are performing well, with ongoing development and plans for esports events to enhance its ecosystem [8] - 哈药股份 achieved significant sales growth in key products, with a focus on optimizing business models and enhancing cash flow management [9] - 香飘飘's milk tea business faced challenges, but new product trials received positive feedback, and the company is focusing on customized products and marketing strategies [10] Group 2: Industry Trends - The automation and digitalization trends in the chemical industry are expected to drive growth opportunities for companies like 博实股份 [1] - The fertilizer industry is seeing a shift towards new types of fertilizers, with companies like 云图控股 expanding their product offerings [2] - The solid-state battery market is gaining traction, with companies like 捷邦科技 investing in advanced materials [3] - The healthcare sector is increasingly integrating AI technology into medical devices, as seen in 可孚医疗's product development [4] - The environmental sector is witnessing significant growth in equipment sales and international business, particularly in waste management [5] - The smartphone market in emerging regions presents opportunities for growth, despite competitive pressures faced by companies like 传音控股 [6] - The electronics and automation sectors are experiencing robust demand, particularly in renewable energy and smart home applications [7] - The gaming industry continues to evolve with new titles and esports events, indicating a strong market presence for companies like 完美世界 [8] - The pharmaceutical industry is focusing on optimizing product strategies and enhancing operational efficiency to drive sales growth [9] - The beverage industry is adapting to market changes with innovative product offerings and targeted marketing strategies [10]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of RMB 4.95 [8][9][5] Core Views - The company reported revenue, net profit attributable to the parent, and net profit excluding non-recurring items for 2024 at RMB 161.8 million, RMB 6.3 million, and RMB 5.9 million respectively, representing year-on-year growth of 5%, 59%, and 80% [1] - The management team and operational reforms since the end of 2023 are expected to drive sustained profit growth and brand value reassessment [1] - Industrial revenue is projected to grow nearly 20% year-on-year in 2024, with expectations of double-digit growth from 2025 to 2027 [2] - The industrial net profit margin is expected to increase significantly in 2024, with a forecasted margin of 7.7% compared to 3.5% in 2023 [3] - The subsidiary, Renmin Tongtai, is facing revenue pressure with a projected decline of 3% year-on-year in 2024 [4] Summary by Sections Financial Performance - For Q1 2025, the company reported revenue of RMB 41.7 million, net profit attributable to the parent of RMB 2.1 million, and net profit excluding non-recurring items of RMB 2.0 million, reflecting year-on-year growth of 1%, 20%, and 28% respectively [1] - The company expects net profit attributable to the parent for 2025 to reach RMB 7.3 million, with a year-on-year growth of 16.5% [5] Revenue and Profitability - The industrial segment's revenue is expected to grow by 19% to RMB 62.8 million in 2024, with a strong performance in the health supplement category [2] - The industrial net profit margin is estimated to be 11.8% in Q1 2025, significantly up from previous periods due to cost reduction and efficiency improvements [3] Subsidiary Performance - Renmin Tongtai's revenue is projected to be RMB 100 million in 2024, down 3% year-on-year, with profits expected to decline by 27% due to market pressures [4] Valuation Metrics - The report provides a PE valuation of 17x for 2025, aligning with the median expectations of comparable companies [5] - The company’s market capitalization is reported at RMB 9.268 billion, with a closing price of RMB 3.68 as of April 28 [9]

江西省吉安市吉州区云章路 36 号 江西新赣江药业股份有限公司 江西新赣江药业股份有限公司招股说明书 证券简称： 新赣江 证券代码： 873167 保荐人（主承销商） （浙江省杭州市西湖区天目山路 198 号财通双冠大厦西楼） 本次股票发行后拟在北京证券交易所上市，该市场具有较高的投资风险。北京证券交易所主要 服务创新型中小企业，上市公司具有经营风险高、业绩不稳定、退市风险高等特点，投资者面临较 大的市场风险。投资者应充分了解北京证券交易所市场的投资风险及本公司所披露的风险因素，审 慎作出投资决定。 中国证监会和北京证券交易所对本次发行所作的任何决定或意见，均不表明 其对注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明 其对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或者保证。 任何与之相反的声明均属虚假不实陈述。 根据《证券法》的规定，股票依法发行后，发行人经营与收益的变化，由发 行人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行承 担股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风险。 1-1-1 声明 发行人及全体董事、监事、高级管理人员 ...